Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
USD2.35
-0.07 (-2.89%)
US NASDAQ Healthcare Biotechnology
Address
822 A1A North 32082
Ponte Vedra, FL, US
Ponte Vedra, FL, US
CEO
Quang X. Pham
Website
cadrenal.com
IPO
2023-01-20
CIK 1937993 ISIN US1276362076
Description
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.35
-0.07 (-2.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
71.0K
Beta
1.61
Float Shares
1.95M
Free Float %
77.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.32% | -10.78% | +16.02% | +1.89% | -54.88% | -18.55% | -58.73% | -73.70% | -91.06% | -91.06% | -91.06% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
2.35
Low
32.00
+1,261.7%
Consensus
32.00
+1,261.7%
Median
32.00
+1,261.7%
High
32.00
+1,261.7%
DCF (Unlevered)
1.72
-26.8%
DCF (Levered)
2.01
-14.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
32.00
+1,261.7%
|
Quality scores
Altman Z-Score
-25.60
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+23.9% Q1'26: +50.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +1,968.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+63.5% Q1'26: +30.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
6.30M
6.30M – 6.30M
|
16.80M
16.80M – 16.80M
+166.7% YoY
|
—
— – —
-100.0% YoY
|
| EBITDA |
-10.65M
|
-13.46M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-10.65M
|
-13.46M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-10.65M
est: -9.28M (-14.8%)
|
-13.24M
est: -12.68M (-4.4%)
|
-11.71M
-15.43M – -7.99M
+7.6% YoY
|
-6.82M
-7.80M – -5.84M
+41.8% YoY
|
-5.20M
-5.76M – -4.65M
+23.7% YoY
|
17.05M
17.05M – 17.05M
+427.6% YoY
|
| SGA |
6.75M
|
9.35M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-8.73
est: -7.60 (-14.9%)
|
-6.64
est: -6.36 (-4.4%)
|
-5.61
-7.74 – -4.01
+11.8% YoY
|
-3.42
-3.91 – -2.93
+39.0% YoY
|
-2.61
-2.89 – -2.33
+23.7% YoY
|
8.55
8.55 – 8.55
+427.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
8
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Quang X. Pham | 6.33M | 48.57% | 3.33M | 3.00M | 3.33M | 3.00M | IN | United States of America | 2024-02-12 | ↗ |
| 2 | The PVBQ Living Trust | 3.00M | 23.04% | — | 3.00M | — | 3.00M | OO | United States of America | 2024-02-12 | ↗ |
| 3 | Armistice Capital, LLC | 1.40M | 9.99% | — | 1.40M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 4 | Steven Boyd | 1.40M | 9.99% | — | 1.40M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 5 | John Raymond Murphy | 594.8K | 5.11% | 594.8K | — | 594.8K | — | IN | United States of America | 2023-03-27 | ↗ |
| 6 | Dubnica Property s.r.o. | 66.3K | 6.20% | — | 66.3K | — | 66.3K | CO | Czech Republic | 2024-10-04 | ↗ |
| 7 | Havlickova 648 a.s. | 66.3K | 6.20% | — | 66.3K | — | 66.3K | CO | Czech Republic | 2024-10-04 | ↗ |
| 8 | Miroslav Dornak | 66.3K | 6.20% | — | 66.3K | — | 66.3K | IN | Czech Republic | 2024-10-04 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - US Sustainability Core 1 ETF DFSU | 0.00% | 2.8K | 0.15% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 80.9K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 346.05 | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 950.16 | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 70.18 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 162.4K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 356.18 | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 193.67 | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 78.39 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 8.62 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.08
Bearish
Ratio by volume
0.19
Bearish
Buys
1
Sells
13
Shares acquired
5.0K
Shares disposed
26.3K
Cash buys
—
Cash sales
13.00
Net activity
-21,258
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-29 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 9,933 | 6.97 | 69.2K | 0 | D | ↗ |
| 2025-12-02 | Golden Lee Scott | Director | A-Award | A | Stock Options | 5,000 | 8.27 | 41.4K | 5,000 | D | ↗ |
| 2025-11-24 | Golden Lee Scott | Director | — | — | Common Stock | 0 | 0.00 | — | 1,667 | D | ↗ |
| 2025-10-27 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 1,800 | 13.99 | 25.2K | 9,933 | D | ↗ |
| 2025-10-27 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,315 | 13.99 | 18.4K | 196,089 | D | ↗ |
| 2025-10-24 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 1,800 | 13.99 | 25.2K | 11,733 | D | ↗ |
| 2025-10-24 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,129 | 14.03 | 15.8K | 197,404 | D | ↗ |
| 2025-10-13 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 1,800 | 14.07 | 25.3K | 13,533 | D | ↗ |
| 2025-10-13 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,800 | 14.15 | 25.5K | 198,533 | D | ↗ |
| 2025-10-09 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 1,693 | 13.99 | 23.7K | 15,333 | D | ↗ |
| 2025-10-09 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,800 | 14.02 | 25.2K | 200,333 | D | ↗ |
| 2025-10-06 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 107 | 13.99 | 1.5K | 17,026 | D | ↗ |
| 2025-10-02 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 500 | 14.13 | 7.1K | 202,133 | D | ↗ |
| 2025-10-01 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 1,700 | 13.99 | 23.8K | 17,133 | D | ↗ |
| 2025-10-01 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 881 | 14.01 | 12.3K | 202,633 | D | ↗ |
| 2025-09-29 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 100 | 14.00 | 1.4K | 18,833 | D | ↗ |
| 2025-09-29 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 419 | 14.01 | 5.9K | 203,514 | D | ↗ |
| 2025-09-25 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 10,900 | 14.05 | 153.2K | 18,933 | D | ↗ |
| 2025-09-25 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 6,790 | 14.09 | 95.7K | 203,933 | D | ↗ |
| 2025-09-24 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 1,500 | 14.00 | 21.0K | 29,833 | D | ↗ |
| 2025-09-24 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 2,581 | 13.99 | 36.1K | 210,723 | D | ↗ |
| 2025-08-28 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 400 | 14.00 | 5.6K | 31,333 | D | ↗ |
| 2025-08-28 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,193 | 13.99 | 16.7K | 213,304 | D | ↗ |
| 2025-08-27 | Szot Matthew K | Officer | S-Sale | D | Common Stock | 1,600 | 14.00 | 22.4K | 31,733 | D | ↗ |
| 2025-08-27 | Pham Quang X | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 3,836 | 13.99 | 53.7K | 214,497 | D | ↗ |
| 2025-02-05 | Ferguson James J. III | Officer | A-Award | A | Stock Options | 60,000 | 19.75 | 1.19M | 60,000 | D | ↗ |
| 2025-02-01 | Cole Jeffrey Scott | Officer | — | D | Stock Options | 150,000 | 0.94 | 141.0K | 0 | — | ↗ |
| 2025-01-23 | Zelenkofske Steven | Director | A-Award | A | Stock Options | 20,000 | 19.79 | 395.8K | 20,000 | D | ↗ |
| 2025-01-23 | WILSON GLYNN | Director | A-Award | A | Stock Options | 20,000 | 19.79 | 395.8K | 20,000 | D | ↗ |
| 2025-01-23 | Szot Matthew K | Officer | A-Award | A | Stock Options | 50,000 | 19.79 | 989.5K | 50,000 | D | ↗ |
| 2025-01-23 | Pham Quang X | Director / Officer / 10% Owner | A-Award | A | Stock Options | 65,000 | 21.77 | 1.41M | 65,000 | D | ↗ |
| 2025-01-23 | MURPHY JOHN RAYMOND | Director | A-Award | A | Stock Options | 20,000 | 19.79 | 395.8K | 20,000 | D | ↗ |
| 2025-01-23 | Lisicki Robert | Director | A-Award | A | Stock Options | 20,000 | 19.79 | 395.8K | 20,000 | D | ↗ |
| 2025-01-23 | Cole Jeffrey Scott | Officer | A-Award | A | Stock Options | 25,000 | 19.79 | 494.8K | 25,000 | D | ↗ |
| 2024-04-10 | Pham Quang X | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 50,000 | 0.00 | — | 3,275,000 | — | ↗ |
| 2024-04-02 | Cole Jeffrey Scott | Officer | A-Award | A | Stock Options | 150,000 | 0.62 | 93.0K | 150,000 | — | ↗ |
| 2024-01-18 | Zelenkofske Steven | Director | A-Award | A | Stock Options | 100,000 | 0.94 | 94.0K | 100,000 | — | ↗ |
| 2024-01-18 | WILSON GLYNN | Director | A-Award | A | Stock Options | 70,000 | 0.94 | 65.8K | 70,000 | — | ↗ |
| 2024-01-18 | Szot Matthew K | Officer | A-Award | A | Stock Options | 250,000 | 0.94 | 235.0K | 250,000 | — | ↗ |
| 2024-01-18 | Pham Quang X | Director / Officer / 10% Owner | A-Award | A | Stock Options | 150,000 | 0.94 | 141.0K | 150,000 | — | ↗ |
| 2024-01-18 | MURPHY JOHN RAYMOND | Director | A-Award | A | Stock Options | 100,000 | 0.94 | 94.0K | 100,000 | — | ↗ |
| 2024-01-18 | Lisicki Robert | Director | A-Award | A | Stock Options | 50,000 | 0.94 | 47.0K | 50,000 | — | ↗ |
| 2024-01-18 | LOSORDO DOUGLAS W | Officer | A-Award | A | Stock Options | 150,000 | 0.94 | 141.0K | 150,000 | — | ↗ |
| 2023-10-23 | Pham Quang X | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 85,000 | 0.00 | — | 3,325,000 | — | ↗ |
| 2023-10-05 | MURPHY JOHN RAYMOND | Director | P-Purchase | A | Common Stock | 2,669 | 0.69 | 1.8K | 614,792 | — | ↗ |
| 2023-10-04 | MURPHY JOHN RAYMOND | Director | P-Purchase | A | Common Stock | 17,331 | 0.70 | 12.1K | 612,123 | — | ↗ |
| 2023-09-05 | Pham Quang X | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 0.90 | 18.0K | 3,410,000 | — | ↗ |
| 2023-09-01 | Pham Quang X | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 0.93 | 18.6K | 3,330,000 | — | ↗ |
| 2023-08-18 | LOSORDO DOUGLAS W | Officer | — | D | Stock Options | 300,000 | 0.64 | 192.0K | — | — | ↗ |
| 2023-07-23 | Lisicki Robert | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-11 | Zelenkofske Steven | Director | — | D | Stock Options | 50,000 | 0.64 | 32.0K | — | — | ↗ |
| 2023-03-16 | MURPHY JOHN RAYMOND | Director | P-Purchase | A | Common Stock | 20,000 | 1.67 | 33.4K | 574,792 | — | ↗ |
| 2023-02-10 | Pham Quang X | Director / Officer / 10% Owner | A-Award | A | Common Stock | 25,000 | 1.94 | 48.5K | 3,300,000 | — | ↗ |
| 2023-01-24 | WILSON GLYNN | Director | C-Conversion | A | Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-01-24 | Szot Matthew K | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 500,000 | — | ↗ |
| 2023-01-24 | MURPHY JOHN RAYMOND | Director | C-Conversion | A | Common Stock | 514,792 | 0.00 | — | 554,792 | — | ↗ |
| 2023-01-19 | Zelenkofske Steven | Director | — | D | Common Stock | 0 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-19 | WILSON GLYNN | Director | — | D | Convertible Promissory Note | 50,000 | 1.00 | 50.0K | — | — | ↗ |
| 2023-01-19 | Szot Matthew K | Officer | — | D | Common Stock | 0 | 0.00 | — | 450,000 | — | ↗ |
| 2023-01-19 | Pham Quang X | Officer | — | I | Common Stock | 0 | 0.00 | — | 3,000,000 | — | ↗ |
| 2023-01-19 | MURPHY JOHN RAYMOND | Director | — | D | Convertible Promissory Note | 514,792 | 1.00 | 514.8K | — | — | ↗ |
| 2022-10-01 | LOSORDO DOUGLAS W | Officer | — | D | Stock Options | 300,000 | 0.64 | 192.0K | 0 | — | ↗ |
| 2022-08-01 | Cole Jeffrey Scott | Officer | — | D | Stock Options | 50,000 | 0.64 | 32.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
2.51M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Quang X. Pham Chief Executive Officer | 708.8K | 407.5K | — | 93.3K | — | 13.8K | 1.22M | 7.63% | ↗ |
| 2 | 2024 | Matthew Szot Chief Financial Officer | 435.9K | 263.1K | — | 155.5K | — | 13.8K | 868.3K | 17.91% | ↗ |
| 3 | 2024 | Jeffrey Cole Chief Operating Officer | 363.7K | 160.4K | — | 155.0K | — | 47.3K | 726.3K | 21.33% | ↗ |
| 4 | 2023 | Quang Pham Chief Executive Officer | 662.5K | 293.0K | — | — | — | 11.6K | 967.0K | 0.00% | ↗ |
| 5 | 2023 | Quang X. Pham Chief Executive Officer | 662.5K | 293.0K | — | — | — | 11.6K | 967.0K | 0.00% | ↗ |
| 6 | 2023 | Matthew Szot Chief Financial Officer | 377.2K | 184.1K | 250.0K | — | — | 33.7K | 844.9K | 29.59% | ↗ |
| 7 | 2023 | Douglas Losordo Chief Medical Officer | 401.0K | 119.1K | — | — | — | 8.5K | 528.7K | 0.00% | ↗ |
| 8 | 2023 | Jeffrey Cole Chief Operating Officer | — | — | — | — | — | 24.9K | 24.9K | 0.00% | ↗ |
| 9 | 2022 | Quang Pham Chief Executive Officer | 350.0K | 337.5K | — | — | — | 128.7K | 816.2K | 0.00% | ↗ |
| 10 | 2022 | Douglas Losordo Chief Medical Officer | — | — | — | 625.2K | — | 23.4K | 648.6K | 96.40% | ↗ |
| 11 | 2022 | Matthew Szot Chief Financial Officer | — | 187.5K | — | — | — | 172.1K | 359.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Quang X. Pham | Chairman & Chief Executive Officer | 1M | male |
| Matthew K. Szot | Co-Founder & Chief Financial Officer | 655.0K | male |
| James J. Ferguson FACC | Chief Medical Officer | 616.9K | — |
| Jeffrey Cole | Chief Operating Officer | 615.4K | male |
| Matthew Boxer | Executive Vice President of Corporate Development | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CVKD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
